Framingham, Massachusetts, U.S., November 11, 2026
Alzheon, Inc. has announced significant progress in its Alzheimer’s disease research programme, highlighting the launch of ORION-E4, its second Phase 3 clinical trial of oral valiltramiprosate (ALZ-801), alongside the expansion of its next-generation oral anti-amyloid drug portfolio. The announcement was made ahead of the 19th Clinical Trials on Alzheimer’s Disease (CTAD) conference, scheduled to take place in Boston, Massachusetts, from November 16 to 19, 2026. The company will present three new scientific posters featuring additional analyses from its 78-week Phase 3 APOLLOE4 clinical trial. These findings include reduced spontaneous brain microbleeds, improvements in Alzheimer’s-associated blood biomarkers and associations between biomarker changes, brain volume preservation and clinical outcomes. The new ORION-E4 study is designed to confirm the cognitive and functional benefits previously observed in the prespecified mild cognitive impairment (MCI) subgroup of patients carrying two copies of the APOE4 genetic variant. The announcement also highlights the progress of ALZ-507, a next-generation once-daily oral anti-amyloid aggregation inhibitor and APOE4 corrector currently undergoing Phase 1 evaluation. Together, these developments strengthen Alzheon’s strategy to advance oral treatments for Alzheimer’s disease and other neurodegenerative conditions.
ORION-E4 Phase 3 Trial Advances Oral ALZ-801 Development
ORION-E4 is a global Phase 3 clinical trial evaluating valiltramiprosate in patients with mild cognitive impairment due to Alzheimer’s disease who carry two copies of the APOE4 gene (APOE4/4 homozygotes). This population represents a genetically defined group with an increased risk of developing Alzheimer’s disease and associated brain complications. The study is designed as a multicenter, randomized, double-blind, placebo-controlled trial involving approximately 550 participants across 150 clinical sites in 12 countries. Participants will receive either 265 mg of oral valiltramiprosate twice daily or placebo over 78 weeks. The primary endpoint will assess changes from baseline in the Clinical Dementia Rating–Sum of Boxes (CDR-SB), a widely used measure of cognitive and functional decline. Secondary assessments will include the Alzheimer’s Disease Assessment Scale-Cognitive Subscale 13 (ADAS-Cog13) and Disability Assessment for Dementia (DAD). The study builds on findings from the earlier APOLLOE4 Phase 3 programme. Although the overall APOLLOE4 population did not demonstrate statistically significant clinical benefits at Week 78, the prespecified MCI subgroup showed encouraging cognitive and functional outcomes. ORION-E4 is specifically designed to confirm these findings in patients at an earlier stage of Alzheimer’s disease, when preserving neuronal function may be particularly important.
APOLLOE4 Findings Show Reduced Brain Microbleeds
One of the important findings highlighted by Alzheon involves the potential safety advantages of valiltramiprosate in patients vulnerable to cerebral amyloid angiopathy (CAA), a condition associated with abnormal amyloid deposits in brain blood vessel walls. In the APOLLOE4 trial, new spontaneous amyloid-related imaging abnormalities involving hemorrhagic changes (ARIA-H), including microbleeds and superficial siderosis, occurred in 15% of patients receiving valiltramiprosate compared with 26% receiving placebo over 78 weeks. This represented a reported 39% reduction in incidence, with a p-value of 0.023. Additionally, concurrent microhemorrhages and superficial siderosis occurred in 1% of treated participants compared with 6% in the placebo group, representing an 89% reduction. Vasogenic edema occurred at similar rates in both groups, at 3.5%, and the reported ARIA events were asymptomatic. The company also highlighted sustained reductions in plasma p-tau217, an important Alzheimer’s disease biomarker associated with abnormal tau pathology. These reductions correlated with preserved brain volume and clinical outcomes in the Phase 3 analysis. The findings will be presented through scientific posters at CTAD 2026.
Advertisement
Alzheon Expands Its Oral Anti-Amyloid Drug Pipeline
Beyond valiltramiprosate, Alzheon is advancing its broader portfolio of oral medicines targeting amyloid aggregation and neurodegenerative disease mechanisms. Its next-generation candidate, ALZ-507, is designed as a once-daily oral small molecule that inhibits the formation of neurotoxic soluble amyloid oligomers while also acting as an APOE4 corrector. ALZ-507 is currently undergoing Phase 1 clinical evaluation, with studies assessing safety, tolerability and pharmacokinetics to guide future dose selection and formulation development. The company is also developing the ALZ-700 series of oral prodrugs, designed to extend its therapeutic platform into additional neurodegenerative conditions. Martin Tolar, MD, PhD, Founder, President and Chief Executive Officer of Alzheon, emphasized the importance of advancing the next generation of oral anti-amyloid medicines and expanding treatment opportunities for individuals at high genetic risk of Alzheimer’s disease. The company’s presentations at CTAD 2026 will include three posters examining plasma p-tau217 biomarkers, spontaneous ARIA rates and additional inflammatory and vascular injury biomarkers from APOLLOE4. The latest developments highlight the growing pharmaceutical research focus on oral disease-modifying treatments for Alzheimer’s disease. Although valiltramiprosate and ALZ-507 remain investigational, further clinical studies will be essential to establish their safety, effectiveness and potential role in future Alzheimer’s treatment strategies.
Source: Alzheon press release
